The framework, first introduced by FDA Commissioner Marty Makary and Center for Biologics Evaluation and Research head Vinay Prasad in November, was criticized for lacking detailed guidance. Agency ...
The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...
Leading phenylketonuria companies, such as NGGT, Jnana Therapeutics, BioMarin (NASDAQ: BMRN), and others, are developing new phenylketonuria treatment drugs that can be available in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results